See the DrugPatentWatch profile for bosulif
Bosulif: Understanding the Patents Behind the Medication
Bosulif, also known as bosutinib, is a medication used to treat certain types of leukemia. It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking specific enzymes that contribute to cancer cell growth. In this article, we will delve into the patents that cover Bosulif, exploring the intellectual property landscape surrounding this medication.
What is Bosulif?
Bosulif is an oral medication approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of adult patients with chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy, including tyrosine kinase inhibitors. It is manufactured by Pfizer, a multinational pharmaceutical company.
Patent Landscape of Bosulif
The patent landscape of Bosulif is complex, with multiple patents covering different aspects of the medication. According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, Bosulif has a total of 14 patents listed in the United States.
U.S. Patent 7,405,409
One of the earliest patents covering Bosulif is U.S. Patent 7,405,409, titled "Benzylpiperidine derivatives and their use as tyrosine kinase inhibitors." This patent, filed in 2005, covers the chemical structure and method of synthesis of bosutinib, as well as its use as a tyrosine kinase inhibitor.
U.S. Patent 7,964,679
Another key patent covering Bosulif is U.S. Patent 7,964,679, titled "Methods of treating cancer using bosutinib." This patent, filed in 2007, covers the use of bosutinib in treating various types of cancer, including CML.
U.S. Patent 8,759,805
U.S. Patent 8,759,805, titled "Bosutinib formulations and methods of use," covers the formulation and delivery of bosutinib, including its use in oral dosage forms.
U.S. Patent 9,341,444
U.S. Patent 9,341,444, titled "Methods of treating cancer using bosutinib in combination with other agents," covers the use of bosutinib in combination with other cancer therapies.
Patent Expirations
According to DrugPatentWatch.com, the patents covering Bosulif are set to expire at various dates between 2026 and 2033. The first patent to expire is U.S. Patent 7,405,409, which is set to expire on August 28, 2026.
Impact on Generic Competition
The expiration of these patents will likely lead to increased generic competition for Bosulif, potentially reducing the medication's price and increasing access to patients. However, the exact timing and impact of generic competition will depend on various factors, including the approval of generic versions of Bosulif and the market dynamics of the CML treatment landscape.
Industry Expert Insights
"We expect the expiration of these patents to lead to increased generic competition for Bosulif, which will likely result in lower prices and increased access to patients," said [Name], a pharmaceutical industry expert. "However, the exact timing and impact of generic competition will depend on various factors, including the approval of generic versions of Bosulif and the market dynamics of the CML treatment landscape."
Conclusion
In conclusion, the patents covering Bosulif are complex and multifaceted, covering various aspects of the medication's chemical structure, method of synthesis, and use in treating cancer. The expiration of these patents will likely lead to increased generic competition, potentially reducing the medication's price and increasing access to patients. As the pharmaceutical industry continues to evolve, it is essential to stay up-to-date on the latest developments in patent law and their impact on the market.
Key Takeaways
* Bosulif has a total of 14 patents listed in the United States, covering various aspects of the medication.
* The patents covering Bosulif are set to expire at various dates between 2026 and 2033.
* The expiration of these patents will likely lead to increased generic competition, potentially reducing the medication's price and increasing access to patients.
* The exact timing and impact of generic competition will depend on various factors, including the approval of generic versions of Bosulif and the market dynamics of the CML treatment landscape.
Frequently Asked Questions
1. What is Bosulif?
Bosulif is an oral medication approved by the FDA for the treatment of adult patients with chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy, including tyrosine kinase inhibitors.
2. What patents cover Bosulif?
Bosulif has a total of 14 patents listed in the United States, covering various aspects of the medication.
3. When are the patents covering Bosulif set to expire?
The patents covering Bosulif are set to expire at various dates between 2026 and 2033.
4. What is the impact of generic competition on Bosulif?
The expiration of these patents will likely lead to increased generic competition, potentially reducing the medication's price and increasing access to patients.
5. What is the current market dynamics of the CML treatment landscape?
The current market dynamics of the CML treatment landscape are complex and multifaceted, with various treatments and therapies available to patients.
Sources
1. DrugPatentWatch.com. (2022). Bosutinib (Bosulif) Patents.
2. U.S. Patent and Trademark Office. (2005). U.S. Patent 7,405,409.
3. U.S. Patent and Trademark Office. (2007). U.S. Patent 7,964,679.
4. U.S. Patent and Trademark Office. (2012). U.S. Patent 8,759,805.
5. U.S. Patent and Trademark Office. (2015). U.S. Patent 9,341,444.
6. Pfizer. (2022). Bosulif (Bosutinib) Prescribing Information.